Literature DB >> 9534029

The pathogenesis of Graves' disease.

B McIver1, J C Morris.   

Abstract

Graves' disease, one of the autoimmune thyroid diseases, is caused by the production of IgG autoantibodies directed against the thyrotropin receptor. These antibodies bind to and activate the receptor, causing the autonomous production of thyroid hormones. Despite recent improvements in our understanding of the cellular and molecular basis of autoimmunity, our currently available treatments for Graves' disease have remained largely unchanged over the last 50 years. Nevertheless, new concepts in immune system regulation hold out the prospect in the future for intervention designed to modify, and possibly cure, the underlying disease process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9534029     DOI: 10.1016/s0889-8529(05)70299-1

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  22 in total

1.  Long-term immunological study in Graves' disease treated with thyroid arterial embolization.

Authors:  Wei Zhao; Bu-Lang Gao; Cang-Zheng Jin; Gen-Fa Yi; Hui-Ying Yang; Hong Li; Dian-Ping Song; Ji-Hong Hu; Yong-Neng Jiang
Journal:  J Clin Immunol       Date:  2008-07-17       Impact factor: 8.317

2.  The yeast mitochondrial carrier Leu5p and its human homologue Graves' disease protein are required for accumulation of coenzyme A in the matrix.

Authors:  C Prohl; W Pelzer; K Diekert; H Kmita; T Bedekovics; G Kispal; R Lill
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 3.  GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis.

Authors:  Matthew J Simmonds
Journal:  Nat Rev Endocrinol       Date:  2013-03-26       Impact factor: 43.330

Review 4.  Thymic hyperplasia in patients with Graves' disease.

Authors:  M Dalla Costa; F A Mangano; C Betterle
Journal:  J Endocrinol Invest       Date:  2014-08-23       Impact factor: 4.256

Review 5.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

6.  Multispectral Optoacoustic Tomography of Benign and Malignant Thyroid Disorders: A Pilot Study.

Authors:  Wolfgang Roll; Niklas A Markwardt; Max Masthoff; Anne Helfen; Jing Claussen; Michel Eisenblätter; Alexa Hasenbach; Sven Hermann; Angelos Karlas; Moritz Wildgruber; Vasilis Ntziachristos; Michael Schäfers
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

7.  High neutrophil-to-lymphocyte ratio is associated with relapse in Graves' disease after antithyroid drug therapy.

Authors:  Mijin Kim; Bo Hyun Kim; Min Hee Jang; Jeong Mi Kim; Eun Heui Kim; Yun Kyung Jeon; Sang Soo Kim; In Joo Kim
Journal:  Endocrine       Date:  2019-11-20       Impact factor: 3.633

8.  Involvement of inducible costimulator ligand (ICOSL) expression in thyroid tissue in hyperthyroidism of Graves' disease patients.

Authors:  Fengming Wang; Tao Yan; Lujun Chen; Xuemin Chen; Tong Liu; Shuang Shen; Ting Li; Li Gao; Ting Wang; Jing Sun; Cuiping Liu; Haorong Wu; Xueguang Zhang; Lei Chen
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

9.  Association of Graves' disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells.

Authors:  Zhiping Sun; Weixue Zhong; Xiang Lu; Bimin Shi; Yibei Zhu; Lei Chen; Guangbo Zhang; Xueguang Zhang
Journal:  J Clin Immunol       Date:  2008-08-14       Impact factor: 8.317

10.  Methimazole upregulates T-cell-derived cytokines without improving the existing Th1/Th2 imbalance in Graves' disease.

Authors:  T Kocjan; B Wraber; A Kocijancic; S Hojker
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.